Last updated: August 28, 2026
Polyethylene glycol 6000, also called macrogol 6000 or PEG 6000, is a solid, water-soluble pharmaceutical excipient used in tablets, capsules, granules, topical products, and selected drug-delivery systems. Its market is mature, fragmented, and driven more by formulation volume, qualification status, raw-material costs, and regional manufacturing capacity than by new intellectual property.
PEG 6000 has limited standalone financial disclosure. Producers generally report it within broader polyether, pharmaceutical excipient, specialty chemical, or performance-materials segments. The commercial outlook is stable to moderately positive, with low-to-mid single-digit volume growth supported by generic drugs, oral solid-dose manufacturing, contract development and manufacturing, and demand for multifunctional excipients.
What is polyethylene glycol 6000 used for in pharmaceutical manufacturing?
PEG 6000 is a high-molecular-weight polyethylene glycol with an average molecular weight of approximately 6,000. It is typically supplied as a white waxy solid, flakes, powder, or granules.
| Attribute |
PEG 6000 profile |
| Common pharmaceutical name |
Macrogol 6000 |
| Chemical family |
Polyethylene glycol |
| CAS number |
25322-68-3 |
| Typical form |
Solid, waxy flakes, powder, or granules |
| Water solubility |
High |
| Primary roles |
Binder, lubricant, plasticizer, solubilizer, carrier, coating aid |
| Main dosage forms |
Tablets, capsules, granules, topical products |
| Key standards |
USP-NF, Ph. Eur., JP, national pharmacopeias |
| Principal buyers |
Generic-drug companies, CDMOs, formulation developers, excipient distributors |
PEG 6000 is used where formulators need water solubility, low volatility, film-forming behavior, and compatibility with many active pharmaceutical ingredients. It can improve powder processing, modify tablet disintegration, and act as a carrier in solid dispersions.
Higher-molecular-weight grades have lower liquidity than PEG 400 or PEG 1500. That makes PEG 6000 more suitable for solid formulations and less suitable for applications requiring a liquid vehicle.
How large is the PEG 6000 pharmaceutical excipient market?
No major producer publicly reports PEG 6000 revenue as a separate business line. Published market studies generally combine several molecular-weight grades and include industrial, cosmetic, and pharmaceutical applications. As a result, PEG 6000 pharmaceutical revenue cannot be isolated reliably from public company filings.
The market has four structural characteristics:
- Pharmaceutical demand is smaller than total industrial and personal-care demand.
- Pharmaceutical-grade material commands a premium over technical-grade PEG.
- Customer qualification creates switching costs.
- Volume growth is steady rather than disruptive.
The most useful commercial indicators are pharmaceutical-grade production capacity, regulatory documentation, regional supply, contract manufacturing activity, and the spread between ethylene oxide input costs and excipient selling prices.
Market growth drivers
Growth is supported by:
- Expansion of generic oral solid-dose production.
- Increased use of solid-dispersion and amorphous-solid-dispersion technologies.
- Growth in outsourced formulation and manufacturing.
- Demand for excipients with established compendial status.
- Regional pharmaceutical localization in India, China, Southeast Asia, and the Middle East.
- Continued use of PEG polymers in topical and modified-release systems.
Growth is constrained by:
- Substitution with povidone, copovidone, poloxamers, HPMC, mannitol, and other binders or solubilizers.
- Limited differentiation between qualified PEG 6000 grades.
- Pressure from generic-drug pricing.
- Energy, ethylene oxide, freight, and compliance costs.
- Customer reluctance to requalify an excipient after formulation approval.
Which companies manufacture or distribute pharmaceutical-grade PEG 6000?
The supply base includes large chemical companies, specialty excipient manufacturers, regional producers, and pharmaceutical distributors. Product names and availability vary by jurisdiction.
| Company or group |
Relevant commercial position |
| BASF |
Pharmaceutical polyethylene glycol grades marketed under the Kollisolv and related excipient portfolios |
| Croda Pharma |
High-purity and specialty excipient products, including polyethylene glycol grades in selected markets |
| Merck |
Pharmaceutical and laboratory distribution of PEG products, including compendial materials |
| Dow |
Polyethylene glycol products historically marketed under Carbowax and related brands, with grade-specific availability |
| India Glycols |
Integrated ethylene oxide and glycol producer with pharmaceutical and industrial PEG exposure |
| Sanyo Chemical Industries |
Polyether and specialty chemical manufacturing capabilities, including PEG-related products |
| Clariant and regional distributors |
Specialty chemical distribution and selected pharmaceutical excipient channels |
| Chinese and Indian manufacturers |
Growing supply of compendial PEG grades, often competing on price and regional availability |
The relevant competitive advantage is not simply polymerization capacity. Pharmaceutical customers evaluate impurity profiles, batch consistency, documentation, audit history, change-control practices, and regulatory support.
What drives PEG 6000 pricing and margins?
PEG 6000 pricing is linked primarily to ethylene oxide economics, plant utilization, energy costs, packaging, freight, and the premium for pharmaceutical-grade production.
Raw-material exposure
Ethylene oxide is the principal upstream input. Its cost reflects ethylene pricing, refinery and cracker economics, energy, and regional supply-demand conditions. Producers with integrated ethylene oxide capacity generally have better cost control than toll manufacturers or distributors.
Grade premium
Pharmaceutical-grade PEG 6000 typically sells at a premium to industrial-grade material because of:
- Controlled impurity limits.
- Validated manufacturing processes.
- Compendial testing.
- Documentation and traceability.
- Dedicated or controlled production environments.
- Customer audits and regulatory support.
The premium is vulnerable when pharmaceutical customers accept alternate suppliers or when generic-drug manufacturers prioritize cost reduction.
Packaging and logistics
PEG 6000 is commonly shipped in bags, drums, or bulk packaging. It is not highly temperature-sensitive compared with many biologic excipients, but storage conditions can affect handling, caking, and product consistency. Freight costs are material for lower-value grades and for cross-border shipments.
Margin profile
PEG 6000 is generally a lower-margin product than highly differentiated drug-delivery excipients or proprietary formulation technologies. Margins improve when a producer has:
- Integrated feedstock operations.
- High plant utilization.
- Large qualified accounts.
- Local production near pharmaceutical customers.
- Multiple molecular-weight grades from the same manufacturing platform.
Margins weaken when supply is long, customers dual-source aggressively, or producers compete primarily on price.
What is the financial trajectory for PEG 6000 from 2024 to 2028?
The base-case outlook is stable growth with periodic price volatility rather than rapid expansion. Pharmaceutical-grade demand should grow faster than mature industrial demand because of generic-drug manufacturing and regional capacity additions.
| Period |
Expected market condition |
Financial effect |
| 2021-2022 |
Higher energy, freight, and chemical-input volatility |
Revenue benefited from pricing, while margins varied by producer |
| 2023 |
Input-cost normalization and inventory correction |
Lower realized pricing in some regions; destocking pressure |
| 2024 |
More balanced supply-demand conditions |
Volume recovery and improved procurement visibility |
| 2025-2026 |
Continued generic and CDMO demand |
Low-to-mid single-digit volume growth is plausible |
| 2027-2028 |
Mature market with regional capacity expansion |
Revenue growth likely depends on volume, mix, and pharmaceutical-grade premiums |
The strongest financial performance should come from producers that combine PEG 6000 with higher-value excipients, specialty polymers, solubilizers, and formulation services. Standalone PEG 6000 producers face greater exposure to commodity pricing.
Revenue exposure by customer type
| Customer segment |
Demand quality |
Pricing power |
| Branded pharmaceutical companies |
Stable, specification-driven |
Moderate |
| Generic-drug manufacturers |
High volume, price-sensitive |
Low to moderate |
| CDMOs |
Growing and diversified |
Moderate |
| Nutraceutical companies |
Variable and cost-sensitive |
Low |
| Cosmetics and personal care |
Broad but substitution-prone |
Low to moderate |
| Industrial users |
Large-volume and cyclical |
Low |
What formulations are protected by PEG 6000 technology?
PEG 6000 itself is not generally a proprietary pharmaceutical technology. It is an established excipient with broad prior use. Protection is more likely to arise from a specific formulation, manufacturing process, particle-engineering method, or drug-delivery system.
Potentially protectable areas include:
- Solid dispersions containing PEG 6000 and a poorly soluble active ingredient.
- Specific drug-to-excipient ratios.
- Hot-melt extrusion processes.
- Controlled-release matrix systems.
- Taste-masking or coating systems.
- PEG 6000-containing topical formulations.
- Particle-size and thermal-processing conditions.
- Combination excipient systems involving PEG 6000 and polymers such as povidone or HPMC.
A formulation patent may cover a particular active ingredient and composition, but it does not normally prevent use of PEG 6000 in unrelated medicines.
What patents protect polyethylene glycol 6000?
The base polymer is a mature chemical known for decades. New composition-of-matter patent protection for ordinary PEG 6000 is therefore unlikely to be commercially central. Patent value generally resides in downstream applications.
| IP category |
Likely relevance |
| PEG 6000 composition patent |
Low for ordinary commercial material |
| Polymerization process patent |
Possible, but often expired or limited to process conditions |
| Purification and impurity-control process |
Potentially relevant to pharmaceutical-grade production |
| Drug formulation patent |
High when linked to a specific active ingredient |
| Drug-delivery patent |
High for controlled release, solubilization, or targeted delivery |
| Manufacturing know-how |
Often more important than patent claims |
| Supplier quality package |
Commercially important but not patent protection |
Patent analysis should therefore focus on the drug product using PEG 6000, not on PEG 6000 as an excipient alone.
What is the FDA regulatory status of PEG 6000?
PEG 6000 is used as an inactive ingredient in pharmaceutical products and is evaluated through the excipient and finished-product regulatory framework. FDA’s Inactive Ingredient Database is the principal public reference for prior use of excipients in approved drug products. Its presence in the database does not create a blanket approval for every route, strength, or formulation [1].
For a new drug application, the sponsor must establish that the selected grade is suitable for the intended formulation and route. Key considerations include:
- Identity and molecular-weight distribution.
- Ethylene oxide and 1,4-dioxane residues.
- Water content.
- Acidity or alkalinity.
- Residue on ignition or sulfated ash.
- Microbial quality where applicable.
- Elemental impurities.
- Batch-to-batch consistency.
The European Pharmacopoeia recognizes macrogol specifications, while USP-NF provides compendial standards for polyethylene glycol materials. Sponsors typically align supplier specifications with the applicable pharmacopoeia and internal quality requirements [2,3].
Does PEG 6000 have Orange Book exclusivity?
No. PEG 6000 is an excipient, not an approved drug product with its own Orange Book listing. It has no standalone New Chemical Entity exclusivity, five-year regulatory exclusivity, Paragraph IV pathway, or Orange Book patent listing.
Paragraph IV litigation can arise when PEG 6000 is included in a generic drug formulation, but the dispute concerns the drug product’s listed patents or other formulation claims. The excipient itself does not generate Paragraph IV exclusivity.
What manufacturing and intellectual-property barriers affect supply?
The main barriers are regulatory and operational rather than patent-based.
Manufacturing barriers
Pharmaceutical-grade PEG 6000 requires:
- Consistent molecular-weight distribution.
- Tight control of low-molecular-weight fractions.
- Residual ethylene oxide and dioxane control.
- Validated cleaning and contamination controls.
- Stable packaging and storage.
- Change-control procedures acceptable to regulated customers.
- Audit-ready quality systems.
A producer may have chemical capacity but still lack approval from major pharmaceutical customers. Qualification can require technical data, stability support, audit completion, and multiple successful commercial batches.
Geographic coverage
Asia is central to global PEG production and pharmaceutical manufacturing. India and China have expanding excipient and generic-drug capacity. Europe remains important for high-specification pharmaceutical materials and regulatory support. North America has substantial demand but relies on a mix of domestic production, multinational suppliers, and imports.
Regional supply risk is highest when customers depend on a single qualified producer. Dual sourcing reduces interruption risk but can pressure pricing.
How does PEG 6000 compare with PEG 400, PEG 3350, and other excipients?
| Excipient |
Physical profile |
Common pharmaceutical role |
Competitive relationship |
| PEG 400 |
Liquid |
Solvent, plasticizer, vehicle |
Competes where liquid processing is suitable |
| PEG 3350 |
Powder or solid |
Osmotic laxative, binder, carrier |
Overlaps in oral formulations |
| PEG 6000 |
Solid, waxy |
Binder, lubricant, carrier, solid dispersion aid |
Favored for solid-dose processing |
| Povidone |
Powder or solution |
Binder, solubilizer |
Major substitute in tablets and solid dispersions |
| Copovidone |
Powder |
Binder, solubilizer, extrusion aid |
Strong alternative in amorphous solid dispersions |
| HPMC |
Polymer powder |
Binder, coating, controlled release |
Competes in modified-release and coating systems |
| Poloxamer |
Solid or liquid |
Solubilizer and wetting agent |
Used in selected delivery systems |
PEG 6000’s main advantage is its established regulatory history and broad compatibility. Its main weakness is limited differentiation and the availability of alternative polymers with stronger performance in specific applications.
What generic launch risks exist for PEG 6000-containing formulations?
Generic competition can reduce excipient demand value even when volume rises. A generic entrant may use the same PEG 6000 grade, a different supplier, or an alternative excipient if bioequivalence and product performance are maintained.
The principal risks are:
- Loss of formulation exclusivity after patent expiry.
- Supplier substitution by the finished-dose manufacturer.
- Price renegotiation after approval.
- Customer consolidation among generic manufacturers.
- Regulatory delays when the excipient source changes.
- Batch failures caused by molecular-weight or impurity variation.
- Shortages caused by regional qualification concentration.
For suppliers, the strongest account protection comes from being embedded in approved formulations and maintaining a complete regulatory-support package.
Key Takeaways
- PEG 6000 is a mature, compendial pharmaceutical excipient with broad use in oral solid-dose and topical formulations.
- Standalone market revenue is not publicly disclosed by major producers.
- Financial performance is driven by ethylene oxide costs, plant utilization, pharmaceutical-grade premiums, and customer qualification.
- The 2024-2028 outlook is stable to moderately positive, with likely low-to-mid single-digit pharmaceutical volume growth.
- Generic drugs and CDMOs are the main volume drivers, but both segments exert pricing pressure.
- PEG 6000 has little standalone patent value because the polymer is long established.
- Formulation, delivery-system, purification, and manufacturing-process patents can create downstream protection.
- PEG 6000 has no standalone Orange Book listing or Paragraph IV exclusivity.
- Quality systems, impurity control, regulatory documentation, and dual sourcing are the main commercial barriers.
- Producers with integrated feedstocks and broader specialty-excipient portfolios should have stronger margin resilience than commodity-focused suppliers.
FAQs
Is PEG 6000 the same as macrogol 6000?
Yes. Macrogol 6000 is the European and international pharmaceutical name commonly used for polyethylene glycol with an average molecular weight of approximately 6,000.
Is PEG 6000 safe as a pharmaceutical excipient?
It has established pharmaceutical use, but safety depends on route, dose, impurity profile, and the finished formulation. Regulatory assessment applies to the specific product and use rather than to an unlimited generic authorization.
Can PEG 6000 be replaced without regulatory approval?
A supplier change may require regulatory assessment, comparability data, or notification. The requirement depends on the drug product, jurisdiction, filing category, and whether the new material meets the approved specification.
Does PEG 6000 create a moat for pharmaceutical manufacturers?
Usually not by itself. Commercial protection is more likely to come from the finished formulation, manufacturing process, clinical data, or regulatory approval.
Which excipient has the strongest competitive alternative to PEG 6000?
Povidone and copovidone are major alternatives in binding and solubilization. HPMC and poloxamers compete in specific controlled-release, coating, and delivery applications.
References
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP-NF.
-
European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.
-
BASF. (n.d.). Pharmaceutical excipients and polyethylene glycol products. BASF SE. https://pharma.basf.com/
-
Croda International Plc. (n.d.). Pharma excipients. Croda Pharma. https://www.croda.com/en-gb/pharma
-
International Council for Harmonisation. (2022). Q3C(R8): Impurities: Guideline for residual solvents. https://www.ich.org/page/quality-guidelines
-
U.S. Food and Drug Administration. (2019). Questions and answers on quality considerations for continuous manufacturing. https://www.fda.gov/աբ
